SOTAC PHARMACEUTICALS LIMITED

Registered Office:
Plot No. PF21 & PF-22/A, Charal Industrial Estate,
Sanand GIDC-II, Sanand,
Ahmedabad- 382110, Gujarat.
CIN.: L24230GJ2015PLC085451

Date: November 13, 2026

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra East, Mumbai-400051

Dear Sir/Ma'am,

Sub: Outcome of board meeting held today i.e. on Friday, November 13, 2026, in terms of second proviso to Regulation 30(6) Of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Sotac Pharmaceuticals Limited (SYMBOL / ISIN: SOTAC/ INE0O2D01012)

In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held today, i.e. on Friday, November 13, 2026, at the Registered Office of the Company situated at Plot No. PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Sanand, Ahmedabad, 382110 Gujarat, India, has inter-alia;

1. Considered, approved and taken on record the Unaudited Standalone & Consolidated Financial Results of the Company for the half year ended on September 30, 2026, along with Statutory Auditor's Limited Review Report as per provisions of Regulation 33 of the SEBI Listing Regulations;

2. Considered and approved all other business as per agenda circulated.

The meeting of Board of Directors of the Company commenced at 4:00 PM (IST) and concluded at 05:30 PM (IST).

Kindly take the same on your records.

Thanking you.

Yours faithfully,

For, Sotac Pharmaceuticals Limited

Patel Sharadkumar

Digitally signed by Patel Sharadkumar
DN: c=IN, o=Personal, postalCode=380061, l=Ahmedabad, st=Gujarat, street=68 Ghatlodia, Ahmedabad City, Ahmadabad City Gujarat India 380061 Near Sun and Step Club, title=7162, 2.5.4.20=b205f5d5261b0afb484230ec84cda0ab339e2ce1731350fa f6a554916c2ee16c, serialNumber=0696672bada9f852ac46529012e3e32ed18b9489a3ecf37a671aadcae1f10030, email=gstsotac@gmail.com, cn=Patel Sharadkumar
Date: 2026.11.13 18:13:11 +05'30'

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad

SOTAC PHARMACEUTICALS LIMITED

Registered Office:
Plot No. PF21 & PF-22/A, Charal Industrial Estate,
Sanand GIDC-II, Sanand,
Ahmedabad- 382110, Gujarat.
CIN.: L24230GJ2015PLC085451

Date: November 13, 2026

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra East, Mumbai-400051

Dear Sir/Ma'am,

Sub: Submission of Unaudited Standalone & Consolidated Financial Results of the Company for the half year ended on September 30, 2026 along with Limited Review Report.

Ref: Sotac Pharmaceuticals Limited (SYMBOL / ISIN: SOTAC/ INE0O2D01012)

With reference to captioned subject and pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the following, for the Half year ended on September 30, 2026.;

1. Consolidated & Standalone Unaudited Financial Results
2. Statement of Consolidated & Standalone Unaudited Asset & Liabilities
3. Consolidated & Standalone Cash Flow Statement
4. Limited Review Report issued by Statutory Auditor of the Company.

Kindly take the same on your records.

Thanking You.

Yours faithfully,

For, Sotac Pharmaceuticals Limited

Patel Sharadkumar

Digitally signed by Patel Sharadkumar
DN: c=IN, o=Personal, postalCode=380061, l=Ahmedabad, st=Gujarat, street=68 Ghatlodia, Ahmedabad City, Ahmedabad City Gujarat India 380061 Near Sun and Step Club, title=7162, 2.5.4.20=b205f5d5261b0afb484230ec84cda0ab339e2ce1731350faf6a554916c2ee16c, serialNumber=0696672bada9f852ac46529012e3e32ed18b9489a3ecf37a671aadcae1f10030, email=gstsotac@gmail.com, cn=Patel Sharadkumar
Date: 2026.11.13 18:13:41 +05'30'

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad

End: A/a-

Keyur Shah & Co.
CHARTERED ACCOUNTANTS

CA KEYUR SHAH
FCA, B.Com, ISA, FAFD Certified

Auditor's Limited Review Report on Unaudited Standalone Financial Results of Sotac Pharmaceutical Limited, for the Half year ended September 30, 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors of,
Sotac Pharmaceutical Limited

We have reviewed the accompanying the statement of Unaudited Standalone financial Results of **Sotac Pharmaceutical Limited** for the half year ended September 30, 2026. The Financial Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this financial statement based on the review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primary to inquire of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results prepared in accordance with applicable standards and other recognized accounting practices and policies has not disclosed the information require to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Keyur Shah & Co.
Chartered Accountants
F.R.No. 141173W

KEYUR SHAH & CO. MEMBERSHIP NO: 153774 CHARTERED ACCOUNTANTS

Keyur Shah
Proprietor
M. No. 153774
UDIN: -26153774BZTHNI8378

Date: - 13th November, 2026
Place: - Ahmedabad

303, Shitiratna, B/s. Radisson Blu Hotel, Nr. Panchvati Circle, Ambawadi, Ahmedabad-380006. Gujarat, INDIA.
Ph. : +91 79 48999595 | M. : +91 999 8484 564 • Website : www.keyurshahca.com
E-mail : keyur@keyurshahca.com, ca.keyurshah2015@gmail.com

SOTAC PHARMACEUTICALS LIMITED
CIN:L24230GJ2015PLC085451
Plot No PF-21 & PF-22/A,Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Unaudited Standalone Financial Result for the Half Year ended 30th September, 2026

(INR in lakhs, unless otherwise stated)

Sr no.	Particulars	Half year ended			Year ended
		30th September, 2026	31st March, 2026	30th September, 2025	31st March, 2026
		Unaudited	Audited	Unaudited	Audited
I)	Revenue From Operations	6,327.14	4,707.63	2,480.32	7,187.95
II)	Other Income	60.56	99.85	109.99	209.84
III)	Total Income (I + II)	6,387.70	4,807.48	2,590.31	7,397.79
IV)	Expenses				
a)	Cost of Material Consumed	1,833.54	2,287.27	1,462.45	3,749.72
b)	Purchase of Stock-in-Trade	3,169.22	1,219.95	70.23	1,290.18
c)	Changes in Inventories of Finished Goods/ Work-In-Progress/ Stock in Trade	31.08	(3.70)	(66.46)	(70.16)
d)	Employee Benefit Expenses	162.66	140.24	112.02	252.26
e)	Finance Costs	58.17	77.90	101.38	179.28
f)	Depreciation and Amortisation Expense	150.82	129.02	121.12	250.14
g)	Other Expenses	446.18	576.73	476.97	1,053.70
	Total Expenses (IV)	5,851.67	4,427.41	2,277.71	6,705.12
V)	Profit/(Loss) Before Exceptional & Extraordinary Items & Tax (III - IV)	536.03	380.07	312.60	692.67
VI)	Exceptional/Prior Period Items	0.05	-	(0.22)	(0.22)
VII)	Profit/(Loss) from ordinary activities Before Extraordinary Items & Tax (V-VI)	536.08	380.07	312.38	692.45
VIII)	Extraordinary Items	-		-	
IX)	Profit Before Tax (VII-VIII)	536.08	380.07	312.38	692.45
X)	Tax Expense				
a)	Current Tax	129.11	103.86	83.94	187.80
b)	Deferred Tax	7.39	2.89	(4.78)	(1.89)
c)	Income Tax Excess Provisions Related to Earlier Years	-	14.72	-	14.72
	Total Tax Expense	136.50	121.47	79.16	200.63
XI)	Profit (Loss) for the period from continuing operations (IX-X)	399.58	258.60	233.22	491.82
XII)	Profit/(loss) from discontinuing operations	-	-	-	-
XIII)	Tax expense of discontinuing operations	-	-	-	-
XIV)	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-
XV)	Profit / (Loss) For The Period/Year (XI+XIV)	399.58	258.60	233.22	491.82
XVI)	Paid up Equity Share Capital (Face value Rs 10 each)	1105.00	1105.00	1105.00	1105.00
XVII)	Reserve & Surplus (Excluding Revaluation Reserve)				4677.04
XVIII)	Earnings Per Equity Share-Basic/Diluted				
	Basic /Diluted earnings per share (In INR) (not annualised, for the Half year ended)	3.62	2.21	2.11	4.45



SOTAC PHARMACEUTICALS LIMITED
CIN:L24230GJ2015PLC085451
Plot No PF-21 & PF-22/A,Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Unaudited Standalone Financial Result for the Half Year ended 30th September, 2026

Notes:

[1] The above Unaudited standalone Financial results for the Half Year Ended on 30th September, 2026 have been prepared by the Company in accordance with Accounting Standards 25 on Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2021 (as amended) and other recognised accounting practices and policies, as applicable and disclosure requirements of Regulation 33 of the SEBI (LODR) Regulations, 2015 (as amended).

[2] The above Unaudited Standalone financial results of Sotac Pharmaceuticals Limited (the Company) for the half year ended 30th September, 2026 were reviewed and recommended by the audit committee and approved by the Board of Directors, at their respective meeting held on 13th November, 2026.

[3] The figures for the Half year ended 31st March, 2026 are the Balancing figures between the audited figures in respect of full Financial year and the unaudited figures in respect of first Half of the Financial year 2025-26.

[4] Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified/recasted wherever considered necessary.

[5] In accordance with regulation 33 of SEBI (LODR) Regulation 2015, the above results have been reviewed by the Statutory Auditors of the Company. These results have been subject to limited review by the Statutory Auditor.

[6] Company is mainly engaged in manufacturing of of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment, hence segment reporting is not applicable to

[7] The Status of investor's complaints during the Year ended on 30th September, 2026 as under:-

Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed during the period	Nil
Complaints resolved at the end of the period	Nil

SOTAC PHARMACEUTICALS LIMITED CIN: L24230GJ2015PLC085451 GUJARAT

For & on behalf of Sotac Pharmaceuticals Limited

Sharad Patel
Chairman & Managing Director
Din No-07252252

Place : **Ahmedabad**
Date : **13th November, 2026**

SOTAC PHARMACEUTICALS LIMITED
CIN:L24230GJ2015PLC085451
Plot No PF-21 & PF-22/A,Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Unaudited Standalone Statement of Assets and Liabilities as at 30th September, 2026

(INR in lakhs, unless otherwise stated)

Particulars	As at 30th September, 2026 Unaudited	As at 31st March, 2026 Audited
I. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	1,105.00	1,105.00
(b) Reserves And Surplus	5,075.79	4,677.04
	6,180.79	**5,782.04**
(2) Share Application Money Pending Allotment	-	-
(3) Non-Current Liabilities		
(a) Long-Term Borrowings	68.45	156.39
(b) Long Term Provisions	7.82	9.32
Total Non-Current Liabilities	**76.27**	**165.71**
(4) Current Liabilities		
(a) Short-Term Borrowings	1,272.56	1,052.52
(b) Trade Payable		
i) Total outstanding dues of micro enterprise and small enterprise	768.17	1,619.48
ii) Total outstanding dues other than micro enterprise and small	1,050.78	506.81
(c) Other Current Liabilities	699.76	199.38
(d) Short-Term Provisions	125.63	134.83
Total Current Liabilities	**3,916.90**	**3,513.02**
TOTAL EQUITY & LIABILITIES	**10,173.96**	**9,460.77**
II.ASSETS		
(1) Non-Current Assets		
(a) Property, Plant & Equipment & Intangible Assets		
(i) Property, Plant & Equipment	1,676.53	1,675.81
(ii) Intangible Assets	529.64	131.99
(iii) Capital Work In -Progress	228.35	170.74
(b) Non-Current Investments	1,218.41	1,218.41
(c) Deferred Tax Assets (Net)	14.36	21.74
Total Non-Current Assets	**3,667.29**	**3,218.69**
(2) Current Assets		
(a) Inventories	1,746.84	1,528.44
(b) Trade Receivables	3,360.71	2,879.05
(c) Cash and Cash Equivalents	25.38	33.91
(d) Short-Term Loans And Advances	506.04	869.58
(e) Other Current Assets	867.70	931.10
Total Current Assets	**6,506.67**	**6,242.08**
TOTAL ASSETS	**10,173.96**	**9,460.77**

SOTAC PHARMACEUTICALS LIMITED CIN: L24230GJ2015PLC085451 GUJARAT

For & on behalf of Sotac Pharmaceuticals Limited

Sharad Patel
Chairman & Managing Director
DIN:07252252

Place: **Ahmedabad**
Date : **13th November, 2026**

SOTAC PHARMACEUTICALS LIMITED

Plot No PF-21 & PF-22/A,Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Unaudited Cash Flow Statement for the Half Year Ended 30th September, 2026

(INR in lakhs, unless otherwise stated)

Particulars	For The Half Year Ended 30th September, 2026	For The Half Year Ended 30th September, 2025
	Unaudited	Unaudited
Cash Flow from Operating Activities		
Net Profit Before Tax Paid	**536.08**	**312.38**
Adjustments for :		
Depreciation And Amortization	150.82	121.12
Interest Income	(46.74)	(106.82)
Dividend income	(0.42)	-
Finance Cost	58.17	101.38
Provision for Gratuity	(1.53)	1.55
Adjustment Related to IPO Expense and Deffered Government Grants	(0.83)	(0.83)
Operating Profit Before Working Capital Changes (a)	**695.55**	**428.78**
Adjustment For Changes In Working Capital :		
Increase / (Decrease) In Trade Payables	(307.34)	260.02
Increase / (Decrease) In Other Current Liabilities	500.38	(5.85)
Increase / (Decrease) In Short and Long term Provisions	5.27	15.85
(Increase) / Decrease In Inventories	(218.40)	(46.24)
(Increase) / Decrease In Trade Receivables	(481.66)	154.60
(Increase) / Decrease In Short Term Loans and Advances	363.54	(36.31)
(Increase) / Decrease In Other Current Assets	63.39	(254.29)
(b)	**(74.82)**	**87.78**
Cash Generated From Operations (a + b)	**620.73**	**516.56**
Taxes Paid (Net Of Refund)	(143.55)	(97.49)
Net Cash Generated From Operations (A)	**477.18**	**419.07**
Cash Flow From Investing Activities		
Addition In Propery, Plant and Equipments And Intagible Assets	(549.22)	(70.75)
Disposals Of Propery, Plant and Equipments And Intagible Assets	0.03	-
Addition In Capital Work In Progress	(57.61)	(60.88)
(Increase) / Decrease In Non Current Investment	-	110.54
Interest Income	46.74	106.82
Dividend income	0.42	-
Net Cash Generated / (Used) in Investing Activities (B)	**(559.64)**	**85.73**

SOTAC PHARMACEUTICALS LIMITED
CIN : L24230GJ2015PLC085451
GUJARAT

SOTAC PHARMACEUTICALS LIMITED

Plot No PF-21 & PF-22/A,Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Unaudited Cash Flow Statement for the Half Year Ended 30th September, 2026

(INR in lakhs, unless otherwise stated)

Particulars	For The Half Year Ended 30th September, 2026	For The Half Year Ended 30th September, 2025
	Unaudited	Unaudited
Cash Flow From Financing Activities		
Repayment of Long Term Borrowings	(87.94)	(258.99)
Increase / (Decrease) In of Short term Borrowings	220.04	(164.03)
Finance Cost	(58.17)	(101.38)
Net Cash Generated / (Used) In Financing Activities (C)	**73.93**	**(524.40)**
Net Increase In Cash And Cash Equivalents (A + B + C)	**(8.53)**	**(19.60)**
Cash And Cash Equivalents beginning of the Year	**33.91**	**44.61**
Cash and cash equivalent at end of year	**25.38**	**25.01**

Notes :

1) Cash and cash equivalents of closing balance comprise of:

Particulars	Half year ended 30 September 2026	Half year ended 30 September 2025
Cash Balance	13.81	14.12
Bank Balance	11.57	10.89
Total	**25.38**	**25.01**

2. The above Cash flow statement has been prepared under the indirect method set out in Accounting Standard-3, "Cash Flow Statement" notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules 2014.

SOTAC PHARMACEUTICALS LIMITED CIN: L24230GJ2015PLC085451 GUJARAT

For & on behalf of Sotac Pharmaceuticals Limited

Sharad Patel
Chairman & Managing Director
Din No-07252252

Place: **Ahmedabad**
Date : **13th November, 2026**

Keyur Shah & Co.
CHARTERED ACCOUNTANTS

CA KEYUR SHAH
FCA, B.Com, ISA, FAFD Certified

Auditor's Limited Review Report on unaudited Consolidated Financial results of Sotac Pharmaceutical Limited, for the Half Year ended September 30, 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors of,
Sotac Pharmaceutical Limited

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Sotac Pharmaceutical Limited** ("the Parent") and its subsidiaries (the Parent and its Subsidiaries together referred to as "the Group"), for the half year ended September 30, 2026 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

1. Sotac Pharmaceutical Limited ("Parent")
2. Sotac Healthcare Private Limited ("Subsidiary")
3. Sotac Lifesciences Private Limited ("Subsidiary")
4. Sotac Research Private Limited ("Subsidiary")

Based on our review conducted and procedures performed as stated in above and based on the statement provided by the Management related to parent & subsidiary, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the

KEYUR SHAH & CO. MEMBERSHIP NO: 153774 CHARTERED ACCOUNTANTS

303, Shitiratna, B/s. Radisson Blu Hotel, Nr. Panchvati Circle, Ambawadi, Ahmedabad-380006. Gujarat, INDIA.
Ph. : +91 79 48999595 | M. : +91 999 8484 564 • Website : www.keyurshahca.com
E-mail : keyur@keyurshahca.com, ca.keyurshah2015@gmail.com

recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the interim financial statements / financial information / financial results of Subsidiaries i.e. "Sotac Healthcare Private Limited" ("Subsidiary"), "Sotac Lifesciences Private Limited ("Subsidiary") and Sotac Research Private Limited ("Subsidiary") included in the Unaudited Consolidated Financial Results, whose interim financial statements / financial information / financial results reflect total revenues of Rs. 1334.51 Lakhs, total net profit/(loss) after tax of Rs. 206.51 Lakhs and net cash flow of Rs. 2.16 Lakhs for the half year ended September 30, 2026, as considered in the Unaudited Consolidated Financial Results, whose interim financial statements / financial information/ financial results have not been reviewed by us. These interim financial statements / financial information / financial results have been provided by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary is based solely on the reports of the Management and the procedures performed by us as stated in above.

Our conclusion on the statement is not modified in respect of the above matters.

For, Keyur Shah & Co.
Chartered Accountants
F.R.No. 141173W



Keyur B. Shah
Proprietor
M No. 153774
UDIN: -26153774WHBBRP5662

Date: 13th November, 2026
Place: Ahmedabad

SOTAC PHARMACEUTICALS LIMITED

CIN:L24230GJ2015PLC085451

Plot No PF-21 & PF-22/A,Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Unaudited Consolidated Financial Result for the half year ended 30th September, 2026

(Rs. in lakhs unless otherwise stated)

Sr no.	Particulars	Half Year ended			Year ended
		30th September, 2026	31st March, 2026	30th September, 2025	31st March, 2026
		Unaudited	Audited	Unaudited	Audited
I)	Revenue From Operations	7,654.95	6,006.32	4,117.61	10,123.93
II)	Other Income	97.24	22.57	12.13	34.70
III)	Total Income (I + II)	7,752.19	6,028.89	4,129.74	10,158.63
IV)	Expenses				
a)	Cost of Material Consumed	2,559.96	3,107.11	2,445.83	5,552.94
b)	Purchase of Stock-in-Trade	3,290.00	908.60	70.23	978.83
c)	Changes in Inventories of Finished Goods/ Work-In-Progress/ Stock in Trade	(352.31)	24.67	(105.47)	(80.80)
d)	Employee Benefit Expenses	282.70	151.08	216.89	367.97
e)	Finance Costs	153.52	225.13	187.70	412.83
f)	Depreciation and Amortisation Expense	298.75	270.56	269.96	540.52
g)	Other Expenses	694.34	807.29	709.20	1,516.49
	Total Expenses (IV)	6,926.96	5,494.44	3,794.34	9,288.78
V)	Profit/(Loss) Before Exceptional & Extraordinary Items & Tax (III - IV)	825.23	534.45	335.40	869.85
VI)	Exceptional/Prior Period Items	(8.16)	(0.00)	(0.22)	(0.22)
VII)	Profit/loss) from ordinary activates before Extraordinary Items and Tax (V-VI)	817.07	534.45	335.18	869.63
VIII)	Extraordinary Items			-	
IX)	Profit Before Tax (VII-VIII)	817.07	534.45	335.18	869.63
X)	Tax Expense				
a)	Current Tax	168.76	108.62	83.94	192.56
b)	Deferred Tax	42.24	39.95	(7.67)	32.28
c)	Income Tax Prior Period		15.46		15.46
	Total Tax Expenses (X)	211.00	164.03	76.27	240.30
XI)	Profit (Loss) for the period from continuing operations (IX-X)	606.07	370.42	258.91	629.33
XII)	Profit/(loss) from discontinuing operations		-	-	
XIII)	Tax expense of discontinuing operations		-	-	
XIV)	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)		-	-	
XV)	Profit / (Loss) For The Period/Year before Minorities (XI+XIV)	606.07	370.42	258.91	629.33
XVI)	Less: Share of Minorities In Subsidiry Companies (Loss)/Profit	75.02	38.34	14.32	52.66
XVII)	Profit/(Loss) for the period	531.05	332.08	244.59	576.67
XVIII)	Paidup Equity Share Capital (Face value Rs 10 each)	1,105.00	1,105.00	1,105.00	1,105.00
XIX)	Reserve & Surplus (Excluding Revaluation Reserve)				4,463.18
XX)	Earnings Per Equity Share-Basic/Diluted				
	Basic /Diluted earnings per share (In INR) (not annualised, for the Half year ended)	4.81	3.01	2.21	5.22

SOTAC PHARMACEUTICALS LIMITED CIN: L24230GJ2015PLC085451 GUJARAT

SOTAC PHARMACEUTICALS LIMITED
CIN:L24230GJ2015PLC085451
Plot No PF-21 & PF-22/A,Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Unaudited Consolidated Financial Result for the half year ended 30th September, 2026

Notes:

[1] The above Unaudited Consolidated Financial Results are prepared in accordance with the recognition and measurement principles laid down in Accounting Standards 25 on Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2021 (as amended) and other recognised accounting practices and policies, as applicable and disclosure requirements of Regulation 33 of the SEBI (LODR) Regulations, 2015 (as amended).

[2] Previous Year's /period's figures have been regrouped/rearranged/recasted wherever considered necessary.

[3] The above Unaudited consolidated financial results of Sotac Pharmaceuticals Limited (the Company) for the half year ended 30th September, 2026 were reviewed and recommended by the audit committee and approved by the Board of Directors, at their respective meeting held on 13th November, 2026.

[4] The Figure for the half year ended 31st March '26 are balancing figures between the audited figures in respect of full financial year and the unaudited figures up to six months ended 30th September, '25.

[5] In accordance with regulation 33 of SEBI(LODR) Regulation 2015, the above results have been reviewed by the Statutory Auditors of the Company. These result have been subject to limited review by statutory auditor.

[6] Company is mainly engaged in manufacturing of of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment hence segment reporting is not applicable to Company.

[7] The Status of investor's complaints during the half year ended on 30th September, 2026 as under:-

Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed during the period	Nil
Complaints resolved at the end of the period	Nil

[8] List of the Entities Consolidated in the Statement:

Name of the Subsidaries Companies	% of Holding as on 30th September, 2026	Relationship	Voting Power Either Directly or Indirectly through Subsidaries
Sotac Healthcare Private Limited	71.00%	Subsidiary	Directly
Sotac Research Private Limited	100.00%	Subsidiary	Directly
Sotac Lifesciences Private Limited	55.77%	Subsidiary	Directly

SOTAC PHARMACEUTICALS LIMITED CIN: L24230GJ2015PLC085451 GUJARAT

For, Sotac Pharmaceuticals Limited

Sharad Patel
DIN:07252252
Chairman & Managing Director

Place : **Ahmedabad**
Date : **13th November, '26**

SOTAC PHARMACEUTICALS LIMITED
CIN:L24230GJ2015PLC085451
Plot No PF-21 & PF-22/A,Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Unaudited Consolidated Statement of Assets and Liabilities As At 30th September, 2026

Particulars	Rs. In Lakhs (unless otherwise stated)	
	As at 30th September, '26 Unaudited	As at 31st March, '26 Audited
I. EQUITY AND LIABILITIES		
Share Holder's Fund		
(a) Share Capital	1,105.00	1,105.00
(b) Reserves and Surplus	5,312.38	4,782.48
	6,417.38	**5,887.48**
Share Application Money Pending Allotment	-	-
Minority Interest	**644.72**	**569.70**
Non-Current Liabilities		
(a) Long-Term Borrowings	1,180.48	1,038.78
(b) Long Term Provisions	15.27	15.10
Total Non-Current Liabilities	**1,195.75**	**1,053.88**
Current Liabilities		
(a) Short-Term Borrowings	2,958.64	2,720.90
(b) Trade Payable		
i) Total outstanding dues of micro enterprise and small enterprise	1,089.11	1,932.38
ii) Total outstanding dues other than micro enterprise and small enterprise	1,484.81	786.77
(c) Other Current Liabilities	849.92	224.96
(d) Short-Term Provisions	161.10	170.97
Total Current Liabilities	**6,543.58**	**5,835.98**
TOTAL EQUITY & LIABILITIES	**14,801.43**	**13,347.04**
II.ASSETS		
Non-Current Assets		
(a) Property, Plant & Equipment & Intangible Assets		
(i) Property, Plant & Equipment	4,582.26	4,577.40
(ii) Intangible Assets	617.13	198.70
(iii) Capital work In -Progress	228.35	170.74
(iv) Goodwill on Consolidation	190.34	190.34
(b) Non-Current Investments	287.37	291.63
(c) Deferred Tax Assets (Net)	55.56	97.81
(d) Long Term Loans and Advances	52.49	52.49
Total Non-Current Assets	**6,013.50**	**5,579.11**
Current Assets		
(a) Inventories	3,346.52	2,707.73
(b) Trade Receivables	3,861.26	3,295.04
(c) Cash and Cash Equivalents	111.43	117.80
(d) Short-Term Loans And Advances	35.41	33.70
(e) Other Current Assets	1,433.31	1,613.66
Total Current Assets	**8,787.93**	**7,767.93**
TOTAL ASSETS	**14,801.43**	**13,347.04**

For, Sotac Pharmaceuticals Limited

SOTAC PHARMACEUTICALS LIMITED CIN: L24230GJ2015PLC085451 GUJARAT

Sharad Patel
DIN:07252252
Chairman & Managing Director

Place: Ahmedabad
Date : 13th November, '26

SOTAC PHARMACEUTICALS LIMITED

CIN : L24230GJ2015PLC085451

Plot No PF-21 & PF-22/A, Charal Industrial Estate, Opp. Teva Pharma, Sanand GIDC-II, Ahmedabad-382110

Unaudited Consolidated Cashflow Statement For The half Year Ended 30th September, 2026

Particulars	Rs. In Lakhs (unless otherwise stated)	
	For the year ended 30th September, 2026	For the year ended 30th September, 2025
	Unaudited	Unaudited
Cash Flow from Operating Activities		
Net Profit before tax paid	817.07	335.18
Adjustments for :		
Depreciation and amortization	298.75	269.96
Interest income	(12.47)	(5.61)
Dividend Income	(0.47)	(0.65)
Provision for Gratuity	0.18	2.06
Finance Cost	153.52	187.70
Prior Period Item	0.53	-
Adjustment Related to IPO Expense and Deffered Government Grants	(1.67)	(1.67)
Operating profit before working capital changes (a)	**1,255.44**	**786.97**
Adjustment for Changes in Working Capital :		
Increase / (Decrease) in Trade Payables	(145.24)	184.40
Increase / (Decrease) in Other Current Liabilities	624.96	(3.36)
Increase / (Decrease) in Short term Provisions	4.30	6.50
(Increase) / Decrease in Inventories	(638.79)	102.45
(Increase) / Decrease in Trade Receivables	(566.22)	136.88
(Increase) / Decrease in Short Term Loans and Advances	(1.71)	0.79
(Increase) / Decrease in Other Current Assets	180.35	(248.85)
Operating profit after working capital changes (b)	**(542.34)**	**178.81**
Cash generated from Operations (a+b)	**713.08**	**965.78**
Taxes paid (net of refund)	(182.93)	(91.01)
Net Cash generated from Operations (A)	**530.16**	**874.77**
Cash Flow from Investing Activities		
Addition in Propery, Plant and Equipments and Intangible Assets	(722.07)	(134.47)
Disposals Of Propery, Plant and Equipments And Intangible Assets	0.03	0.80
(Increase) / Decrease in Capital Work in Progress	(57.61)	(60.88)
(Increase) / Decrease in of Loans and advances		(0.03)
(Increase) / Decrease In Non Current Investments	4.26	110.54
Interest income	12.47	5.61
Dividend Income	0.47	0.65
Net Cash generated / (used) in Investing Activities (B)	**(762.45)**	**(77.78)**

SOTAC PHARMACEUTICALS LIMITED CIN: L24230GJ2015PLC085451 GUJARAT

SOTAC PHARMACEUTICALS LIMITED

CIN : L24230GJ2015PLC085451

Plot No PF-21 & PF-22/A, Charal Industrial Estate, Opp. Teva Pharma, Sanand GIDC-II, Ahmedabad-382110

Unaudited Consolidated Cashflow Statement For The half Year Ended 30th September, 2026

Particulars	Rs. In Lakhs (unless otherwise stated)	
	For the year ended 30th September, 2026 Unaudited	For the year ended 30th September, 2025 Unaudited
Cash Flow from Financing Activities		
Repayment of Long Term Borrowings	(272.30)	(478.52)
Proceeds from Long Term Borrowings	414.00	-
Increase / (Decrease) of Short term Borrowings	237.74	(67.15)
Finance Cost	(153.52)	(187.70)
Net Cash generated / (used) in Financing Activities (C)	**225.93**	**(733.37)**
Net Increase in Cash and Cash Equivalents (A+B+C)	**(6.37)**	**63.62**
Cash and Cash Equivalents as on 1st April, 2026	117.80	156.39
Cash and Cash Equivalents as on 30th September, 2026	**111.43**	**220.01**

Notes :

1) Cash and cash equivalents of closing balance comprise of:

Particulars	Half year ended 30 September 2026	Half year ended 30 September 2025
Cash Balance	36.14	37.85
Bank Balance	20.30	127.16
Recurring Deposit	55.00	55.00
Total	**111.43**	**220.01**

2) The above Cash flow statement has been prepared under the indirect method set out in Accounting Standard-3, "Cash Flow Statement" notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules 2014.

For, Sotac Pharmaceuticals Limited

SOTAC PHARMACEUTICALS LIMITED CIN: L24230GJ2015PLC085451 GUJARAT

Sharad Patel
DIN:07252252
Chairman & Managing Director

Place: **Ahmedabad**
Date : **13th November, '26**